Skip to main content
Premium Trial:

Request an Annual Quote

RayBiotech, Innopsys Ink Microarray Co-marketing Deal

NEW YORK (GenomeWeb News) – RayBiotech today announced a deal with Innopsys to co-market each other's technologies.

Under the agreement, RayBiotech and Innopsys will co-promote RayBiotech's G-Series and Quantibody series of antibody arrays and array testing services with Innopsys' Innoscan laser microarray scanning platforms.

The partnership is the first of a series of deals that RayBiotech plans to pursue in 2012 in order to accelerate adoption of the firm's products and services, President, COO, and Co-founder Rani Huang said. In addition to deals with industry players, RayBiotech hopes to partner with academic and government institutions, he added.

Innopsys CEO Stephane Le Brun said in a statement that the company sees proteomics as a high-growth area. "[T]hus we view a partnership with RayBiotech as a solid reinforcement to our already growing presence in this sector," he said.

Financial and other terms of the deal were not disclosed.

RayBiotech, based in Norcross, Ga., develops antibody and protein array technologies. Innopsys is based in Carbonne, France and develops microarray scanners and associated software.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.